Identifying ductal carcinoma in situ cases not requiring surgery to exclude postoperative upgrade to invasive ductal carcinoma

被引:2
|
作者
Nakayama, Sayuka [1 ]
Masuda, Hiroko [1 ]
Miura, Sakiko [2 ]
Kuwayama, Takashi [1 ]
Hashimoto, Rikako [1 ]
Taruno, Kanae [1 ]
Sawada, Terumasa [3 ]
Akashi-Tanaka, Sadako [1 ]
Nakamura, Seigo [1 ]
机构
[1] Showa Univ Hosp, Dept Breast Surg Oncol, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428666, Japan
[2] NTT Med Ctr Tokyo, Dept Diagnost Pathol, Tokyo, Japan
[3] NTT Med Ctr Tokyo, Dept Breast Surg Oncol, Tokyo, Japan
关键词
Ductal carcinoma in situ; LORETTA trial; Low-grade DCIS; Overtreatment; Active surveillance; CORE-NEEDLE BIOPSY; LYMPH-NODE BIOPSY; BREAST-CANCER; KI-67; EXPRESSION; PREDICTORS; UNDERESTIMATION; MAMMOGRAPHY; METASTASIS; RECURRENCE; MANAGEMENT;
D O I
10.1007/s12282-022-01338-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Prospective cohort studies are being conducted worldwide to identify a low-grade group of ductal carcinoma in situ (DCIS) that does not require surgery. However, to do this, it is necessary to predict which cases, diagnosed with preoperative DCIS, will be upgraded to invasive ductal carcinoma (IDC) after surgery. Methods In this study, we evaluated the frequency of IDC upgrades in patients who were preoperatively diagnosed with DCIS at Showa University using the criteria of ongoing clinical trials. We divided our cases into those that could be enrolled in the ongoing trial and those that could not. Moreover, we evaluated whether CNB, which is allowed only in Japanese clinical trials, is related to the IDC mixture. Results There were 211 (52.1%) cases that matched the criteria of the U.K. and Netherlands trials, of which 62 (29.4%) were upgraded to IDC. A total of 113 (27.9%) cases met the criteria for clinical trials in Japan and the U.S., 25 (22.1%) of which were upgraded to IDC and 47 (34.6%) which matched when considering biopsy methods. The number of cases upgraded to IDC decreased to four (8.5%). Conclusions This study demonstrated that there were a certain number of mixed IDC. We will pay attention to the results of ongoing clinical trials regarding how the presence of this mixed IDC affects the prognosis in non-surgery cases. Careful follow-up is recommended for non-surgical treatment.
引用
收藏
页码:610 / 617
页数:8
相关论文
共 50 条
  • [31] Inhibition of the Transition of Ductal Carcinoma In Situ to Invasive Ductal Carcinoma by a Gemini Vitamin D Analog
    Wahler, Joseph
    So, Jae Young
    Kim, Yeoun Chan
    Liu, Fang
    Maehr, Hubert
    Uskokovic, Milan
    Suh, Nanjoo
    CANCER PREVENTION RESEARCH, 2014, 7 (06) : 617 - 626
  • [32] Radiation therapy for ductal carcinoma in situ
    Punglia, Rinaa S.
    Burstein, Harold J.
    Weeks, Jane C.
    CANCER, 2012, 118 (03) : 603 - 611
  • [33] The Surgical Management of Ductal Carcinoma In Situ
    Kumar, Shicha
    Sacchini, Virgilio
    BREAST JOURNAL, 2010, 16 : S49 - S52
  • [34] Diagnostic Value of Ultrasound Elastography in the Differentiation of Breast Invasive Ductal Carcinoma and Ductal Carcinoma In situ
    Shi, Jian
    Chen, Luzeng
    Wang, Bin
    Zhang, Hong
    Xu, Ling
    Ye, Jingming
    Liu, Yinhua
    Shao, Yuhong
    Sun, Xiuming
    Zou, Yinghua
    CURRENT MEDICAL IMAGING, 2023, 19 (03) : 286 - 291
  • [35] Ductal carcinoma in situ: analysis of 250 cases
    Boehm, J.
    Zikan, M.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2014, 35 (05) : 525 - 529
  • [36] Prediction of Occult Invasive Disease in Ductal Carcinoma in Situ Using Deep Learning Features
    Shi, Bibo
    Grimm, Lars J.
    Mazurowski, Maciej A.
    Baker, Jay A.
    Marks, Jeffrey R.
    King, Lorraine M.
    Maley, Carlo C.
    Hwang, E. Shelley
    Lo, Joseph Y.
    JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 2018, 15 (03) : 527 - 534
  • [37] Ductal Carcinoma In Situ of the Breast
    Vaidya, Yash
    Vaidya, Pradeep
    Vaidya, Tanvi
    INDIAN JOURNAL OF SURGERY, 2015, 77 (02) : 141 - 146
  • [38] Ductal carcinoma in situ: an overview
    Duggal, Shivani
    Robin, Julieta
    Julian, Thomas B.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (08) : 955 - 962
  • [39] Underestimation of invasive breast carcinoma in patients with initial diagnosis of ductal carcinoma in situ: Size matters
    Bouzon Alejandro, Alberto
    Iglesias Lopez, Angela
    Acea Nebril, Benigno
    Garcia Jimenez, Maria Lourdes
    Diaz Carballada, Carlota Czestokowa
    Varela Romero, Jose Ramon
    CIRUGIA ESPANOLA, 2021, 99 (09): : 655 - 659
  • [40] Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
    Pilewskie, Melissa
    Stempel, Michelle
    Rosenfeld, Hope
    Eaton, Anne
    Van Zee, Kimberly J.
    Morrow, Monica
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (11) : 3487 - 3493